NCT05583357进行中（未招募）早期 1 期
A Single Center, Randomized, Open-labeled, Blind Endpoint Evaluation, Exploratory Clinical Study to Evaluate the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 as a Booster Dose in Participants Aged 18 Years and Older Vaccinated 2-dose or 3-dose Inactivated COVID-19 Vaccine
适应症
试验速览
- 阶段
- 早期 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Neutralizing antibody GMT of Omicron BA.5
研究概览
简要总结
It is a single center, randomized, open-labeled, blind endpoint evaluation, exploratory clinical study to evaluate the safety and immunogenicity of bivalent vaccine V-01D-351 as a booster.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults aged 18 years and older at time of consent, male or female;
- •Normal body temperature;
- •Meet either of the following conditions:
- •Received completed primary immunization of 2 doses of CoronaVac 6-15 months ago;
- •Received completed 3 doses of CoronaVac 5-9 months ago;
- •Female participants who are not pregnant at the time of enrollment (urine pregnancy test is negative), nor during lactating; and has no birth plan and agree to take effective contraception in 7 months after enrollment; and took effective and acceptable contraceptive methods in the previous 2 weeks before the enrollment;
- •Be able and willing to complete the study during the entire study and follow-up period;
- •Participants who have the ability to understand the study process, sign the informed consent form voluntarily , and be able to comply with the requirements of the clinical study protocol.
排除标准
- •Serious chronic diseases or uncontrolled diseases;
- •Uncontrolled neurological disorders, epilepsy;
- •Received any inactivated vaccine within 1 week or received any attenuated vaccines within 4 weeks;
- •Patients with congenital or acquired immunodeficiency;
- •History of severe allergy or be allergic to any components of the test vaccines;
- •History of hereditary hemorrhagic tendency or coagulation dysfunction;
- •Patients with malignant tumors and other patients have a life expectancy less than 1 year;
- •Refuse to sign the informed consent form or inability to complete follow-ups as required by the protocol;
- •History of previous COVID-19 infection;
- •Pregnant or breastfeeding women, or females of childbearing potential who not agree to or able to take effective and acceptable contraceptive methods during the study;
- •Participants who have participated in other clinical trials within 3 months or are participating in other clinical trials;
- •Those considered by the investigator as inappropriate to participate in the study.
结局指标
主要结局
Neutralizing antibody GMT of Omicron BA.5
时间窗: 28 days after vaccination
Neutralizing antibody GMT of the most prevalent SARS-CoV-2 variant (Omicron BA.5)
次要结局
- Neutralizing antibody GMT of other SARS-CoV-2 variants(7 days, 14 days, 28 days, 3 months, 6 months and 12 months after vaccination)
- Neutralizing antibody titer of other SARS-CoV-2 variants (MRNT)(7 days, 14 days, 28 days, 3 months, 6 months and 12 months after vaccination)
- SAE and AESI(Within 12 months after vaccination)
- RBD antibody level(7 days, 14 days, 28 days, 3 months, 6 months and 12 months after vaccination)
- Neutralizing antibody titer of other SARS-CoV-2 variants (SVNT)(7 days, 14 days, 28 days, 3 months, 6 months and 12 months after vaccination)
- Total IgG antibody level(7 days, 14 days, 28 days, 3 months, 6 months and 12 months after vaccination)
- Spike protein antibody level(7 days, 14 days, 28 days, 3 months, 6 months and 12 months after vaccination)
- AEs(30 minutes, 0-7 days, 0-28 days after vaccination)
- Specific cytokine secretion levels(7 days, 14 days, 28 days, 3 months, 6 months and 12 months after vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
早期 1 期
A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5COVID-19 PandemicNCT05585567Livzon Pharmaceutical Group Inc.48
进行中（未招募）
2 期
A trial of normal versus higher dose acetylcysteine in patients with paracetamol overdoseParacetamol overdoseInjury, Occupational Diseases, PoisoningISRCTN17516192Accord (United Kingdom)90
已完成
不适用
Evaluation of the Safety and Performance Characteristics of Mesofiller Aox for the Correction of Mild and Moderate Facial Wrinkles.Skin AgingSkin WrinklingNCT06486740Mesoestetic Pharma Group S.L.55
已完成
不适用
Efficacy and Performance Evaluation of mIntense L+AS 25 mg/ml Hyaluronic Acid for the Correction of Moderate to Deep Wrinkles and FoldsSkin AgingSkin WrinklingNCT06451822Mesoestetic Pharma Group S.L.42
已完成
不适用
Evaluation of the Safety and Performance Characteristics of Mesofiller Mesotox for the Correction of Wrinkles and Rehydration of the Face.Skin AgingSkin WrinklingNCT06477432Mesoestetic Pharma Group S.L.52